Local view for "http://purl.org/linkedpolitics/eu/plenary/2016-03-10-Speech-4-276-750"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20160310.25.4-276-750"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"I was happy to support, along with my ALDE colleagues, the amendments to this file. It was important to amend this regulation considering the proposal by the Commission on veterinary medicinal products which now consolidates the regulation on veterinary medicines into one regulation rather than being fragmented across a number. The new regulation will thus cover all routes granting marketing authorisations for veterinary medicinal products in the Union.
The reason for this modification, and why I supported it, was because the needs of the veterinary sector differ substantially from those of the human sector in relation to medicines. In the veterinary sector there are many different animal species, which creates both a fragmented market and the need for major investments in order to extend the authorisation of medicines existing for one animal species to another.
Within the text, I was happy that the level and structure of the fees payable to the European Medicines Agency will not be set via implementing acts as the Commission intended but through co-decision, which will allow the Parliament to have clear oversight into the budgetary expenses of the EMA. In addition, I was happy that there will be annual assessments of antimicrobial resistance in the EU."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples